

Method Migration of Size-Exclusion and Ion-Exchange Methods for Monoclonal Antibody Analysis from HPLC to the Arc Premier System

Brooke M. Koshel, David Dao, Robert E. Birdsall, Ying Qing Yu

Waters Corporation

Abstract

Transferring methods between internal laboratories and external contract organizations is a key part of analytical development of biopharmaceuticals. The sending and receiving laboratories are faced with the challenges of each laboratory updating instrumentation on their own respective timelines as older instrumentation is phased out, as well as each laboratory having instrumentation from different vendors. Regardless of these differences, any data generated between the two laboratories must be demonstrated to be comparable. Although development and quality control laboratories may be slow to replace existing technologies, modern technologies can benefit legacy methods and future development activities as part of lifecycle management. The Arc Premier System was introduced as a modern UHPLC that can also support more routine assays traditionally run on HPLC platforms. Size exclusion and ion-exchange chromatography methods, two assays commonly used in quality control, showed reproducible results when migrating methods from an Alliance HPLC System. Differences in retention time and peak area percent were negligible between the two platforms, instilling

confidence that the legacy method could be replicated successfully on the Arc Premier System. To further take advantage of the more modern UHPLC technology, column chemistries were also updated to achieve results that could be more reliably quantitated through improved chromatographic performance.

Benefits

- Method equivalency demonstrated when migrating legacy SEC and IEX methods from HPLC to an Arc Premier System, a UHPLC platform
- Modernization of LC platforms and column chemistries work together to future-proof biopharmaceutical laboratories

Introduction

Because the lifecycle of biopharmaceutical products spans many years, it is critical that the analytical methods used to ensure product quality are robust and reliable. These methods further require that the instrument platforms and column chemistries used for analysis can deliver consistent results. In the biopharmaceutical space, size exclusion chromatography (SEC) and ion-exchange chromatography (IEX) are among the most common assays used to assess product quality of monoclonal antibodies (mAbs). As legacy methods are transferred between both internal and external laboratories, it is critical that these methods can be replicated, regardless of environmental factors that may differ between the sending and receiving laboratories.

In this work, SEC and IEX methods are migrated from an Alliance HPLC System, an industry standard stainless-steel HPLC system, to an Arc Premier System, a modern UHPLC platform. The Arc Premier System is designed with MaxPeak High Performance Surfaces (HPS) Technology, which was specifically developed to mitigate unwanted adsorption of metal-sensitive analytes to metal surfaces.¹ Although this technology has demonstrated benefits for RPLC and HILIC assays due to the intrinsic charge properties of the analyte and metal surface which are generally not observed in SEC and IEX due to the high-ionic strength of the mobile phases, it is important that new technologies can be more broadly deployed and support existing methods. After demonstrating successful method migration using traditional SEC and IEX methods, updated column chemistries are used in combination with the Arc Premier System to show that modern technologies can both support legacy methods as well as offer distinct advantages over these more conventional approaches.

Experimental

Sample Description

Formulated trastuzumab was prepared to 10 mg/mL in mobile phase per USP <129> for SEC experiments. Trastuzumab was diluted in water to 1 mg/mL for IEX experiments. Sample was prepared fresh prior to each analysis.

LC Conditions

LC systems:	Alliance HPLC System with 2489 UV/Visible Detector Arc Premier System with 2489 UV/Visible Detector
SEC	
Columns:	BioSuite Diol (OH) Column 250 Å, 5 µm, 7.8 x 300 mm, USP Classification L59 (p/n: 186002165) BioResolve SEC mAb Column, 200 Å, 2.5 µm, 7.8 x 300 mm (p/n: 186009441)
Wavelength:	280 nm
Injection volume:	20 µL
Column temp.:	Ambient
Flow rate:	0.500 mL/min
Mobile phase:	200 mM potassium phosphate buffer, 250 mM KCl, pH 6.2

Method: 30 min isocratic run time

IEX

Columns: Protein-Pak Hi Res CM Column, 7 μ m, 4.6 x 100 mm (p/n: 186004929)
Protein-Pak Hi Res SP Column, 7 μ m, 4.6 x 100 mm (p/n: 186004930)
BioResolve SCX mAb Column, 3 μ m, 4.6 x 100 mm (p/n: 186009060)

Wavelength: 280 nm

Injection volume: 20 μ L

Column temp.: 25 $^{\circ}$ C

Mobile phase A: 20 mM MES buffer pH 6.6

Mobile phase B: 20 mM MES buffer pH 6.6, 1 M NaCl

Gradient

Time (min)	Flow (mL/min)	%A	%B
Initial	0.800	100.0	0.0
1.00	0.800	100.0	0.0
2.00	0.800	94.0	6.0
4.00	0.800	94.0	6.0
19.00	0.800	85.0	15.0
20.00	0.800	50.0	50.0
20.10	0.800	100.0	0.0
30.00	0.800	100.0	0.0

Data Management

Empower 3 Chromatography Data Software FR4

Results and Discussion

Demonstrating Method Equivalency of Traditional HPLC Methods

SEC is the method of choice for studying size variants, such as high molecular weight species (HMWS) or aggregates, in the development and quality control of mAbs. Aggregation can occur due to properties inherent to the mAb or through external factors during manufacturing and storage and has been linked to increased immunogenicity. Legacy SEC methods using columns with large particle sizes and HPLC systems with high system dispersion provide adequate resolution of the HMWS and the monomer peak. Although low molecular weight species (LMWS) are also present, capillary electrophoresis has historically been used for more reliable quantitation as HPLC-based methods provide insufficient resolution. While advances in SEC have allowed for better resolution of the LMWS, it is still important that as new LC platforms are incorporated into an evolving

laboratory environment, that these systems continue to support legacy methods and generate the same results as more traditional LC platforms.

To assess a legacy SEC method, method conditions were selected according to USP <129> which provides analytical procedures for purity assessment of mAbs by SEC, capillary electrophoresis, and oligosaccharide analysis. SEC conditions are summarized in Table 1 and were used without making any changes to the proposed method. A series of six injections of trastuzumab were run on an Alliance HPLC System and an Arc Premier System. Representative chromatograms show similar profiles between the two platforms (Figure 1).

Parameter	Description
Column	7.8 mm × 30 cm; 5 µm packing L59
Column temperature	Ambient
Autosampler temperature	Maintain at 2–8 °C
Flow rate	0.5 mL/min
Injection volume	20 µL
Run time	30 min
Detector	UV 280 nm
Sample solution	Dilute the sample to 10 mg/mL in mobile phase if dilution is required. Similarly, a blank should be prepared using an equivalent dilution of formulation buffer in mobile phase.
Mobile phase	Prepare by mixing 10.5 g of dibasic potassium phosphate, 19.1 g of monobasic potassium phosphate, and 18.6 g of potassium chloride per L of water. Verify that the pH is 6.2 ± 0.1. Pass through a membrane filter of ≤0.45 µm or smaller pore size.

Table 1. Summary of SEC method conditions outlined in USP <129> Analytical Procedures of Recombinant Therapeutic Monoclonal Antibodies.




Figure 1. SEC method migration of trastuzumab. Method conditions are outlined in USP <129> and were used without any changes. The LMWS 1 is included in the monomer peak area as it is not adequately resolved.

Retention time and peak area were further compared to address method equivalency. Table 2 reports the average retention time and relative retention time for six injections on each LC platform for the HMWS, monomer, and LMWS 2 (LMWS 1 co-elutes with the monomer peak). The difference in retention time between the two systems is less than 0.6 minutes for each of the peaks. To account for shifts in retention time, the difference in relative retention time is also reported, and is negligible. Peak area was also conserved between platforms (Table 3). The difference in peak area between platforms was no greater than 0.07% for six injections, which was reported for the monomer peak. The HMWS and LMWS 2 which are far less abundant, were also reliably quantitated with differences in peak area of 0.064% and 0.006%, respectively. Furthermore, results obtained on a single LC platform were also repeatable. The %RSD did not exceed 2% for any of the peaks on either platform. The combination of retention time and peak area show that the Arc Premier System yields results that align with a legacy LC system.

	Alliance HPLC System (N=6)		Arc Premier System (N=6)		Difference between platforms	
	RT (min)	RRT	RT (min)	RRT	Δ RT	Δ RRT
HMWS	13.778	0.851	13.359	0.851	0.419	0.000
Monomer/LMWS 1	16.184	1.000	15.697	1.000	0.486	0.000
LMWS 2	19.894	1.229	19.326	1.231	0.568	-0.002

Table 2. Retention time (RT) and relative retention time (RRT) comparison of the Alliance HPLC System and Arc Premier System (N=6). Differences in retention time are negligible for all peaks when compared between LC systems.

	Alliance HPLC System (N=6)		Arc Premier System (N=6)		Difference between platforms
	Peak area (%)	RSD (%)	Peak area (%)	RSD (%)	Δ Peak area
HMWS	0.638	0.223	0.574	0.542	0.064
Monomer/LMWS 1	99.123	0.005	99.193	0.005	-0.070
LMWS 2	0.238	1.717	0.233	1.347	0.006

Table 3. Peak area comparison of the Alliance HPLC System and Arc Premier System (N=6). Results are similar between the two LC platforms as well as repeatable within individual instruments.

To test the broader applicability of the Arc Premier System, IEX was also evaluated as a routine assay performed in QA/QC environments. IEX is a charge-based separation used for quantitation of acidic and basic impurities where traditional methods most frequently use a salt gradient (versus a pH gradient) for elution. Because IEX methods need to be optimized for the specific analyte, guidance documents offering more generalized method recommendations are not available. IEX method conditions were first optimized using a Protein-Pak Hi Res CM Column (7 μ m, 4.6 x 100 mm) on the Alliance HPLC System to represent a method using more traditional LC and column technologies. Six injections of 1 mg/mL trastuzumab were run on the Alliance HPLC System and the Arc Premier System for comparison. Chromatographic profiles were observed to be highly similar between the two platforms (Figure 2). As expected, a shift in retention time is observed due to systematic differences in dwell volume (Alliance HPLC System: 1050 μ L; Arc Premier System: 950 μ L). Although legacy methods often use long gradient/run times, a shorter method was used because chromatographic profiles and assignment of acidic and

basic variants match historical results obtained internally.^{2,3}




Figure 2. IEX method migration of trastuzumab. Slight shifts in retention time can be observed due to differences in dwell volume between the two systems (Alliance HPLC System: 1050 μ L; Arc Premier System: 950 μ L). Dwell volume can be calculated according to the method outlined by Hong and McConville.⁴

To further evaluate the results between LC platforms, Table 4 reports the retention time and relative retention time of the seven peaks identified in Figure 2. The average difference in retention time is 0.149 minutes, which aligns with the difference in dwell volume between the two platforms (0.149 minutes \times 0.8 mL/min = 0.126 mL). When correcting for this difference through reporting relative retention time, the difference is negligible. Relative peak area for these same seven peaks is also highly similar, where individually reported peaks are within error of one another (Figure 3). When reporting the total acidic and basic variants, results between the two platforms were within 0.04 and 0.11 percent of one another, respectively. The Alliance HPLC System and the Arc Premier System independently produced repeatable data while also demonstrating that comparable results were obtained when comparing the two platforms.

	Alliance HPLC System (N=6)		Arc Premier System (N=6)		Difference between platforms	
	RT (min)	RRT	RT (min)	RRT	Δ RT	Δ RRT
A1	7.062	0.818	6.934	0.818	0.128	0.000
A2	7.459	0.864	7.327	0.865	0.132	0.000
A3	7.836	0.908	7.698	0.909	0.138	-0.001
Main peak	8.630	1.000	8.473	1.000	0.157	0.000
B1	9.041	1.048	8.876	1.048	0.166	0.000
B2	9.437	1.094	9.270	1.094	0.167	0.000
B3	9.699	1.124	9.545	1.127	0.154	-0.003

Table 4. Retention time (RT) and relative retention time (RRT) comparison of the Alliance HPLC System and Arc Premier System (N=6). Differences in retention time are negligible for all peaks when compared between LC systems.




Figure 3. Peak area comparison of the Alliance HPLC System and Arc Premier System (N=6).

Results are similar between the two LC platforms for individual peaks as well as for the total number of acidic and basic variants.

Future-Proofing the Biopharmaceutical Lab with New and Modern Technologies

By replacing legacy LC platforms and introducing more modern instrumentation into the laboratory, new chemistries with smaller particle sizes can also be incorporated to build more robust methods, offering benefits such as increased resolution and faster run times. In Figure 4A, SEC data was collected for trastuzumab using method conditions from USP <129> where the recommended column was updated to a column with smaller particle (and pore) size. In the legacy method, LMWS 1 is generally not accurately quantitated as it is similar in size to the monomer and elutes as a back shoulder. By updating the column chemistry to the BioResolve SEC mAb Column, this back-shoulder peak can now be resolved and was determined to over-estimate the peak area percent of the monomer peak by approximately 0.6% (Figure 4A).

To see if these same benefits could be achieved in IEX, the Arc Premier System was used to evaluate 7 μm column

chemistries with both strong cation-exchangers (Protein-Pak Hi Res SP Column) and weak cation-exchangers (Protein-Pak Hi Res CM Column) and the BioResolve SCX mAb column, which is a strong cation-exchange column with 3 μm particle size (Figure 4B). When using the same method conditions across all three columns, the BioResolve SCX mAb Column resolved the greatest number of variants. Furthermore, the total number of acidic and basic variants aligns with results reported for the Protein-Pak Hi Res SP Column. While the Protein-Pak Hi Res CM Column, the weak cation-exchange column, reports a similar peak area purity to the other two columns, the total number of acidic and basic variants is more variable when compared to the strong cation-exchange columns. Unlike SEC which can show resolution gains from minimizing LC system dispersion alone, IEX methods can benefit from further optimization for different column chemistries and analytes. Because in IEX there is generally a trade-off when resolving acidic and basic variants- to improve the resolution of one the resolution of the other will typically decrease, it can be beneficial to tailor methods to better balance the resolution of each impurity group.




Figure 4. Comparing results on the Arc Premier System using conventional columns and updated column chemistries. Figure 4A. SEC of trastuzumab using the BioSuite Diol (OH) Column (250 Å, 5 µm, 7.8 x 300 mm) and the BioResolve SEC mAb Column (200 Å, 2.5 µm, 7.8 x 300 mm). The BioResolve mAb Column can resolve the LMWS 1 fragment that elutes with the monomer peak when using the conventional SEC column. Figure 4B. IEX of trastuzumab using the Protein-Pak Hi Res CM Column (7 µm, 4.6 x 100 mm), the Protein-Pak Hi Res SP Column (7 µm, 4.6 x 100 mm) and the BioResolve SCX mAb Column (3 µm, 4.6 x 100 mm). The SP Column and BioResolve SCX are strong cation-exchange columns and produce results more similar to one another. (Other than updating the column chemistries, all method conditions were kept the same when comparing the columns.)

Conclusion

Traditional SEC and IEX methods employ HPLC systems and column chemistries having large particle size to avoid exceeding pressure limitations of these more aged platforms. As more modern LC platforms are incorporated into the laboratory, these new systems must demonstrate that they can produce comparable results to existing technologies. This work demonstrates that legacy SEC and IEX methods could be migrated from an Alliance HPLC System to an Arc Premier System with negligible differences in retention time and peak area

percent. By combining the Arc Premier System with modern UHPLC columns, data could be more accurately interpreted through greater efficiency, selectivity, and enhanced resolution.

References

1. DeLano, M., Walter, T. H., Lauber, M. A., Gilar, M., Jung, M. C., Nguyen, J. M., Boissel, C., Patel, A. V., Bates-Harrison, A., Wyndham, K. D. Using Hybrid Organic-Inorganic Surface Technology to Mitigate Analyte Interactions with Metal Surfaces in UHPLC. *Anal. Chem.* 2021, 93, 14, 5773–5781.
2. Koshel, B. M., Birdsall, R. E., Yu, Y. Q. Method Development Tools for More Efficient Screening of Biopharmaceutical Method Conditions Using the ACQUITY Arc Bio System Part 2 of 2: Screening SEC and IEX Conditions in a Single Experiment. Waters Application Note, 2020 [720006854EN](https://www.waters.com/nextgen/in/en/library/application-notes/2020/method-development-tools-for-more-efficient-screening-of-biopharmaceutical-method-conditions-using-the-acquity-arc-bio-system-part-2-of--screening-sec-and-iex-conditions-in-a-single-experiment.html) <
<https://www.waters.com/nextgen/in/en/library/application-notes/2020/method-development-tools-for-more-efficient-screening-of-biopharmaceutical-method-conditions-using-the-acquity-arc-bio-system-part-2-of--screening-sec-and-iex-conditions-in-a-single-experiment.html>> .
3. Yang, H., Warren, B., Koza, S. Development of Monoclonal Antibody Charge Variant Analysis Methods Using a BioResolve SCX mAb Column. Waters Application Note, 2019, [720006477EN](https://www.waters.com/nextgen/in/en/library/application-notes/2019/development-monoclonal-antibody-charge-variant-analysis-methods-bioresolve-scx-mab-column.html) <
<https://www.waters.com/nextgen/in/en/library/application-notes/2019/development-monoclonal-antibody-charge-variant-analysis-methods-bioresolve-scx-mab-column.html>> .
4. Hong, P., McConville, PR. Dwell Volume and Extra-Column Volume: What Are They and How Do They Impact Method Migration. Waters White Paper, 2016, [720005723EN](https://www.waters.com/webassets/cms/library/docs/720005723en.pdf) <
<https://www.waters.com/webassets/cms/library/docs/720005723en.pdf>> .

Featured Products

Arc Premier System <<https://www.waters.com/waters/nav.htm?cid=135083359>>

Alliance HPLC System <<https://www.waters.com/534293>>

[2489 UV/Visible \(UV/Vis\) Detector <https://www.waters.com/515198>](https://www.waters.com/515198)

[Empower Chromatography Data System <https://www.waters.com/10190669>](https://www.waters.com/10190669)

720007283, Revised August 2021

© 2022 Waters Corporation. All Rights Reserved.

[Terms of Use](#)

[Privacy](#)

[Trademarks](#)

[Sitemap](#)

[Careers](#)

[Cookies](#)

[Préférences de cookies](#)